Gilead signs deals with Indian companies for low-cost HIV drug
(Reuters) - Gilead Sciences Inc signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug emtricitabine in developing countries.
Under deals with Ranbaxy Laboratories, Strides Arcolab and Mylan Inc's India unit, Gilead will provide technology and funding to help reduce manufacturing costs of the drug, the companies said.
Gilead, which sells the drug under the Emtriva brand, is the world's largest maker of branded drugs to treat the human immunodeficiency virus -- the cause of AIDS.
(Reporting by Shailesh Kuber; Editing by Viraj Nair)
- Tweet this
- Share this
- Digg this
- Supreme Court turns the clock back with gay sex ban
- CORRECTED-UPDATE 2-India's Supreme Court turns the clock back with gay sex ban
- UPDATE 3-GM to halt car production in Australia, industry in crisis
- Obama and Castro shake hands, Zuma humiliated at Mandela memorial
- Google feeds India and China from data centres next door
While focus on the “core” communities has helped keep the disease in check, authorities must “follow the epidemic” and target internal migrants and truckers to widen the scope of prevention efforts, two UNAIDS officials said in an interview with India Insight. Article